Literature DB >> 28320717

In Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977).

Ryuta Kishii1, Yuko Yamaguchi2, Masaya Takei2.   

Abstract

Lascufloxacin exhibited a broad spectrum of activity against various clinical isolates. Furthermore, lascufloxacin showed the most potent activity against Gram-positive bacteria among the quinolones tested and incomplete cross-resistance against existing quinolone-resistant strains. Enzymatic analysis indicated that lascufloxacin had potent inhibitory activity against both wild-type and mutated target enzymes. These results suggest that lascufloxacin may be useful in treating infections caused by various pathogens, including quinolone-resistant strains.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  antimicrobial activity; antimicrobial agents; quinolones

Mesh：

Substances：

Year:  2017        PMID： 28320717      PMCID： PMC5444182          DOI： 10.1128/AAC.00120-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.

Authors:  M Takei; H Fukuda; R Kishii; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan.

Authors:  T Yamaguchi; Y Hirakata; K Izumikawa; Y Miyazaki; S Maesaki; K Tomono; Y Yamada; S Kamihira; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014.

Authors:  Helio S Sader; Robert K Flamm; Rodrigo E Mendes; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

5.  Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.

Authors:  H Fukuda; S Hori; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

6.  High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study).

Authors:  Jae-Hoon Song; Sook-In Jung; Kwan Soo Ko; Na Young Kim; Jun Seong Son; Hyun-Ha Chang; Hyun Kyun Ki; Won Sup Oh; Ji Yoeun Suh; Kyong Ran Peck; Nam Yong Lee; Yonghong Yang; Quan Lu; Anan Chongthaleong; Cheng-Hsun Chiu; M K Lalitha; Jennifer Perera; Ti Teow Yee; Gamini Kumarasinghe; Farida Jamal; Adeeba Kamarulzaman; Navaratnam Parasakthi; Pham Hung Van; Celia Carlos; Thomas So; Tak Keung Ng; Atef Shibl
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

7.  Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).

Authors:  Robert K Flamm; Rodrigo E Mendes; Patricia A Hogan; Jennifer M Streit; James E Ross; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 8.  Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications.

Authors:  Takeshi Saraya; Daisuke Kurai; Kazuhide Nakagaki; Yoshiko Sasaki; Shoichi Niwa; Hiroyuki Tsukagoshi; Hiroki Nunokawa; Kosuke Ohkuma; Naoki Tsujimoto; Susumu Hirao; Hiroo Wada; Haruyuki Ishii; Koh Nakata; Hirokazu Kimura; Kunihisa Kozawa; Hajime Takizawa; Hajime Goto
Journal:  Front Microbiol       Date:  2014-08-11       Impact factor: 5.640
  8 in total
  9 in total

1.  In Vitro Mechanistic Study of the Distribution of Lascufloxacin into Epithelial Lining Fluid.

Authors:  Kouhei Ohya; Junichi Takano; Shigeru Manita
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions.

Authors:  Mika Murata; Kosuke Kosai; Shunsuke Yamauchi; Daisuke Sasaki; Norihito Kaku; Naoki Uno; Yoshitomo Morinaga; Hiroo Hasegawa; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Mukae; Katsunori Yanagihara
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 3.  Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

4.  Intrapulmonary Pharmacokinetics of Lascufloxacin in Healthy Adult Volunteers.

Authors:  Hidetoshi Furuie; Sayoko Tanioka; Keiko Shimizu; Shigeru Manita; Masaharu Nishimura; Hisao Yoshida
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.

Authors:  Shu-Chen Kuo; Yung-Chih Wang; Mei-Chen Tan; Wei-Cheng Huang; Yih-Ru Shiau; Hui-Ying Wang; Jui-Fen Lai; I-Wen Huang; Tsai-Ling Lauderdale
Journal:  J Antimicrob Chemother       Date:  2021-07-15       Impact factor: 5.790

Review 6.  Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Andrew Song; Isaac Yin Sum Mok; Drosos E Karageorgopoulos; Apostolos Armaganidis; Sotirios Tsiodras; Jeffrey Lipman
Journal:  Microorganisms       Date:  2020-01-30

Review 7.  Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update.

Authors:  Emily N Drwiega; Keith A Rodvold
Journal:  Clin Pharmacokinet       Date:  2021-10-15       Impact factor: 6.447

8.  Identification of Novel Antibacterials Using Machine Learning Techniques.

Authors:  Yan A Ivanenkov; Alex Zhavoronkov; Renat S Yamidanov; Ilya A Osterman; Petr V Sergiev; Vladimir A Aladinskiy; Anastasia V Aladinskaya; Victor A Terentiev; Mark S Veselov; Andrey A Ayginin; Victor G Kartsev; Dmitry A Skvortsov; Alexey V Chemeris; Alexey Kh Baimiev; Alina A Sofronova; Alexander S Malyshev; Gleb I Filkov; Dmitry S Bezrukov; Bogdan A Zagribelnyy; Evgeny O Putin; Maria M Puchinina; Olga A Dontsova
Journal:  Front Pharmacol       Date:  2019-08-27       Impact factor: 5.810

Review 9.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.